Aprea Therapeutics Promotes Gregory S. Wessels to Chief Commercial Officer and Announces Governance Changes
18 sept. 2020 08h00 HE
|
Aprea Therapeutics
BOSTON, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that...
Innovation Pharmaceuticals Announces Publication of Independent Research on Kevetrin, the Company’s p53 Drug Candidate, in Oncology Reports
08 sept. 2020 10h00 HE
|
Innovation Pharmaceuticals Inc.
BEVERLY, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to announce the publication of...
Aprea Therapeutics to Present at Upcoming Investor Conferences
03 sept. 2020 08h00 HE
|
Aprea Therapeutics
BOSTON, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Aprea Therapeutics Reports Second Quarter 2020 Financial Results and Provides Update on Business Operations
11 août 2020 16h15 HE
|
Aprea Therapeutics
BOSTON, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Aprea Therapeutics Announces Expansion of Clinical Trial Evaluating Eprenetapopt for the Front-Line Treatment of TP53 Mutant Acute Myeloid Leukemia (AML)
16 juil. 2020 07h00 HE
|
Aprea Therapeutics
Commenced expansion cohort in combination with venetoclax and azacitidineAdded cohort to be activated in combination with azacitidine BOSTON, July 16, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics,...
Aprea Therapeutics Appoints Fouad Namouni, M.D. and Richard Peters, M.D., Ph.D. to Board of Directors
29 juin 2020 07h00 HE
|
Aprea Therapeutics
BOSTON, June 29, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that...
Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 (Eprenetapopt) and Azacitidine in Patients with TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia at the 25th European Hematology Association Annual Meeting
12 juin 2020 06h00 HE
|
Aprea Therapeutics
57% CR and 75% ORR rate by IWG criteria in all evaluable MDS patients 12.1 months median OS in intention-to-treat MDS patients with 9.7 months median duration of follow-up 13.7 months median OS...
Aprea Therapeutics Completes Full Enrollment of Phase 3 Clinical Trial in TP53 Mutant Myelodysplastic Syndromes (MDS)
03 juin 2020 08h00 HE
|
Aprea Therapeutics
Topline data expected by year-end 2020Applications for US and EU regulatory approval planned for 2021 BOSTON, June 03, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a...
Aprea Therapeutics to Present at 2020 RBC Capital Markets Global Healthcare Conference
18 mai 2020 08h00 HE
|
Aprea Therapeutics
BOSTON, May 18, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Aprea Therapeutics Reports First Quarter 2020 Financial Results and Provides Update on Business Operations
15 mai 2020 07h30 HE
|
Aprea Therapeutics
BOSTON, May 15, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...